While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.
is expected to report quarterly earnings of $2.06 a share on sales of $7.8 billion before the market opens Thursday, Apr. 25, based on a FactSet survey of 14 analysts. Quarterly estimates have risen less than 1 cent a share in the past month. AbbVie is currently trading at a price-to-forward-earnings ratio of 8.9 based on the 12-month estimates of 16 analysts surveyed by FactSet.
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures. Plaque psoriasis is the most common form of psoriasis, a a chronic skin condition. The approval of Skyrizi, an injectable drug, is based on results from AbbVie's global Phase 3 psoriasis program, which assessed the safety and efficacy of the drug in adults with moderate to severe plaque psoriasis.
These two drug stocks have been the industry's biggest losers this year. Which is the better buy now?
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
Can the big drugmaker meet Wall Street's expectations this time around?
AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When most people think of marijuana stocks, the last thing they think of is dividends. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges. The company remains one of the most popular marijuana pharmaceuticals developers.